earnings
SA
NASDAQ · SABS
SAB Biotherapeutics, Inc.
Healthcare · Biotechnology
$3.39
Down-$0.02 (-0.59%)
Updated Sep 17, 2026, 12:34 PM
SID Score
2.8/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 34.31M
- P/E ratio
- 2.04
- Dividend yield
- 0.00%
- 52-week range
- $3.28 – $5.15
- Volume
- 452.39K
- Avg. volume
- 331K
Price performance
SABS price history
1M range · 20 trading sessions · Daily adjusted prices
SABS closed at $3.39 after 20 trading sessions, down 10.32% for the selected period.
- Last close
- $3.39
- Period change
- -10.32%
- Period low
- $3.39
- Period high
- $3.93
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 16, 2026 | $3.45 | $3.49 | $3.35 | $3.39 | 452.39K |
| Sep 15, 2026 | $3.45 | $3.5082 | $3.32 | $3.41 | 284.26K |
| Sep 14, 2026 | $3.42 | $3.51 | $3.395 | $3.46 | 237.5K |
| Sep 11, 2026 | $3.45 | $3.54 | $3.38 | $3.41 | 712.05K |
| Sep 10, 2026 | $3.48 | $3.53 | $3.395 | $3.42 | 328.63K |
| Sep 9, 2026 | $3.61 | $3.65 | $3.47 | $3.48 | 200.97K |
| Sep 8, 2026 | $3.70 | $3.75 | $3.62 | $3.63 | 171.26K |
| Sep 4, 2026 | $3.72 | $3.75 | $3.695 | $3.72 | 110.63K |
| Sep 3, 2026 | $3.76 | $3.79 | $3.71 | $3.72 | 161.59K |
| Sep 2, 2026 | $3.70 | $3.77 | $3.60 | $3.75 | 300.42K |
| Sep 1, 2026 | $3.65 | $3.749 | $3.65 | $3.70 | 202.28K |
| Aug 31, 2026 | $3.76 | $3.80 | $3.69 | $3.71 | 201.14K |
| Aug 28, 2026 | $3.91 | $3.99 | $3.785 | $3.79 | 202.6K |
| Aug 27, 2026 | $3.86 | $3.93 | $3.835 | $3.93 | 282.22K |
| Aug 26, 2026 | $3.80 | $3.90 | $3.75 | $3.88 | 274.42K |
| Aug 25, 2026 | $3.65 | $3.81 | $3.61 | $3.81 | 359.37K |
| Aug 24, 2026 | $3.78 | $3.78 | $3.61 | $3.62 | 602.69K |
| Aug 21, 2026 | $3.74 | $3.83 | $3.70 | $3.78 | 195.67K |
| Aug 20, 2026 | $3.75 | $3.7607 | $3.66 | $3.70 | 229.63K |
| Aug 19, 2026 | $3.83 | $3.88 | $3.76 | $3.78 | 701.27K |
Latest SABS news
The latest Smart Investors Daily articles mentioning SABS.
Stock researchMarket Activity · Short Interest
Loading stock research…

